DE60223037D1 - Chitin-mikropartikel und ihre medizinische verwendung - Google Patents

Chitin-mikropartikel und ihre medizinische verwendung

Info

Publication number
DE60223037D1
DE60223037D1 DE60223037T DE60223037T DE60223037D1 DE 60223037 D1 DE60223037 D1 DE 60223037D1 DE 60223037 T DE60223037 T DE 60223037T DE 60223037 T DE60223037 T DE 60223037T DE 60223037 D1 DE60223037 D1 DE 60223037D1
Authority
DE
Germany
Prior art keywords
medical use
chitin microparticles
gamma
treatment
chitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223037T
Other languages
English (en)
Other versions
DE60223037T2 (de
Inventor
Peter Strong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CMP Therapeutics Ltd
Original Assignee
CMP Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120030A external-priority patent/GB0120030D0/en
Priority claimed from GB0206864A external-priority patent/GB0206864D0/en
Application filed by CMP Therapeutics Ltd filed Critical CMP Therapeutics Ltd
Application granted granted Critical
Publication of DE60223037D1 publication Critical patent/DE60223037D1/de
Publication of DE60223037T2 publication Critical patent/DE60223037T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60223037T 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung Expired - Lifetime DE60223037T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0120030 2001-08-16
GB0120030A GB0120030D0 (en) 2001-08-16 2001-08-16 Chitin Microparticles and their medical uses
GB0206864 2002-03-22
GB0206864A GB0206864D0 (en) 2002-03-22 2002-03-22 Chitin microparticles and their medical uses
PCT/GB2002/003814 WO2003015744A1 (en) 2001-08-16 2002-08-16 Chitin microparticles and their medical uses

Publications (2)

Publication Number Publication Date
DE60223037D1 true DE60223037D1 (de) 2007-11-29
DE60223037T2 DE60223037T2 (de) 2008-07-24

Family

ID=26246442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223037T Expired - Lifetime DE60223037T2 (de) 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US7498038B2 (de)
EP (1) EP1416916B1 (de)
JP (1) JP2005501845A (de)
CN (1) CN1543338B (de)
AT (1) ATE375786T1 (de)
AU (1) AU2002324124B2 (de)
CA (1) CA2457027C (de)
DE (1) DE60223037T2 (de)
ES (1) ES2295391T3 (de)
PT (1) PT1416916E (de)
WO (1) WO2003015744A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113835A1 (en) * 2006-04-05 2007-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-allergy compositions
US20080014281A1 (en) * 2006-06-16 2008-01-17 Florida Atlantic University Chitin Micro-Particles As An Adjuvant
WO2007148048A1 (en) 2006-06-20 2007-12-27 Cmp Therapeutics Limited Compositions comprising chitin microparticles and their medical uses
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
EP2081545B1 (de) * 2006-10-30 2019-07-03 Biosys Health Inc. Verfahren zur Herstellung von Chitinmikropartikeln
CN100531742C (zh) * 2007-01-18 2009-08-26 宁波普爱生物工程有限公司 一种抗肿瘤氨基多糖超细微粒及其制备方法
EP2123261A1 (de) * 2008-05-20 2009-11-25 Stallergenes S.A. Speichelklebende Partikelformulierung zur Induzierung von antigenspezifischer Immuntoleranz
JP5705112B2 (ja) * 2008-07-30 2015-04-22 エスティーシー．ユーエヌエム ドライパウダー吸入エアロゾル用の大径キャリア粒子を含む製剤
US9005899B2 (en) * 2010-04-01 2015-04-14 Mingchi University Of Technology Chitin-induced immune response based method for diagnosing allergic asthma in patients
WO2011135578A1 (en) * 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
CN103327831A (zh) * 2010-08-17 2013-09-25 姆柯瓦克斯有限公司 包含几丁质微粒的营养组合物
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
RU2748976C2 (ru) 2015-06-04 2021-06-02 Аморфикал Лтд. Композиции аморфного карбоната кальция для ингаляции, подъязычного или трансбуккального введения
CN109952510A (zh) * 2016-05-13 2019-06-28 应用酵素医学研究所株式会社 收集用于预测过敏发病风险的数据的方法
WO2018078616A1 (en) 2016-10-25 2018-05-03 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5543041A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4873092A (en) 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP2824185B2 (ja) * 1993-03-22 1998-11-11 旭化成工業株式会社 魚類免疫賦活剤
JPH07188291A (ja) * 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
JPH0959164A (ja) * 1995-08-21 1997-03-04 San Five Kk 抗炎症剤
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
WO2002089839A1 (en) 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
ATE216264T1 (de) 1996-07-10 2002-05-15 West Pharm Serv Drug Res Ltd Gentherapiesystem zur zielung des endotheliums
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
JP4097737B2 (ja) * 1997-04-07 2008-06-11 ユニチカ株式会社 鼻口腔用抗炎症散布剤
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
EP1035833B1 (de) 1997-12-02 2005-08-31 Archimedes Development Limited Zusammensetzungen zur nasalen verabreichung
GB9800912D0 (en) 1998-01-17 1998-03-11 Danbiosyst Uk New composition
CA2327670A1 (en) * 1998-04-08 1999-10-14 Darrel Lavern Allen Pulmonary and nasal delivery of raloxifene
EP1113818B1 (de) * 1998-09-18 2006-05-17 Dynavax Technologies Corporation Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
WO2000056362A2 (en) 1999-03-24 2000-09-28 The Secretary Of State For Defence Polycationic carbohydrates as immunostimulants in vaccines
KR100345466B1 (ko) 1999-10-08 2002-07-26 한국과학기술연구원 콜레라 독소 ｂ 소단위로 표면 수식된 마이크로스피어
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2002009674A2 (en) 2000-07-28 2002-02-07 Inhale Therapeutic Systems, Inc. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US6773695B2 (en) 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
WO2002034287A2 (en) 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
WO2003086454A1 (en) 2002-04-18 2003-10-23 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
WO2007148048A1 (en) * 2006-06-20 2007-12-27 Cmp Therapeutics Limited Compositions comprising chitin microparticles and their medical uses

Also Published As

Publication number Publication date
EP1416916A1 (de) 2004-05-12
CA2457027C (en) 2011-10-11
EP1416916B1 (de) 2007-10-17
US20090214666A1 (en) 2009-08-27
DE60223037T2 (de) 2008-07-24
PT1416916E (pt) 2008-01-25
US7498038B2 (en) 2009-03-03
CA2457027A1 (en) 2003-02-27
WO2003015744A1 (en) 2003-02-27
AU2002324124B2 (en) 2007-01-04
ES2295391T3 (es) 2008-04-16
JP2005501845A (ja) 2005-01-20
CN1543338B (zh) 2010-06-16
US8551501B2 (en) 2013-10-08
US20040234614A1 (en) 2004-11-25
CN1543338A (zh) 2004-11-03
ATE375786T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
ATE375786T1 (de) Chitin-mikropartikel und ihre medizinische verwendung
HUP0301003A2 (hu) Kazeinből származó peptidek és terápiás alkalmazásuk
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
NO20064192L (no) Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
IL184749A0 (en) Anti-interferon gamma antibodies and pharmaceutical compositions containing the same
BR0011838A (pt) Elementos misturadores estáticos empilhados
WO2003101397A3 (en) Tetravalent dengue vaccines
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
SE0302304D0 (sv) Novel compounds
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
ATE410235T1 (de) Behandlung von ballastwasser
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
ATE431399T1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
TW200612981A (en) Treatment of cardiomyopathy and of endothelial dysfunction
AU2003253894A8 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
ATE386542T1 (de) Mittel zur stimulation des immunsystems
ATE390144T1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition